Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Journal:

The New England Journal of Medicine

Published:

2025-10-20

DOI:

10.1056/nejmoa2511734

Affiliations:

24

Authors:

18

Go to article

Institutions	Authors	Share
Gilead, United States of America (USA)	4.000000	0.22
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.06
Kyushu Cancer Center, Japan	1.000000	0.06
UW Medicine, United States of America (USA)	1.000000	0.06
Cancer Institute and Hospital, CAMS & PUMC, China	1.000000	0.06
Samsung Medical Center (SMC), South Korea	1.000000	0.06
Agostino Gemelli University Polyclinic, Italy	1.000000	0.06
Yonsei Cancer Hospital, South Korea	1.000000	0.06
Latin American Cooperative Oncology Group (LACOG), Brazil	1.000000	0.06
Ziekenhuis aan de Stroom (ZAS), Belgium	1.000000	0.06
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.06
University of São Paulo (USP), Brazil	1.000000	0.06
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany	0.500000	0.03
Heidelberg University Hospital at Medical Faculty Heidelberg, Uni Heidelberg, Germany	0.500000	0.03
UPMC Hillman Cancer Center (UPCI), United States of America (USA)	0.500000	0.03
UPMC Magee-Womens Hospital, United States of America (USA)	0.500000	0.03
IOB Institute of Oncology, Spain	0.125000	0.01
Hospital Beata María Ana, Spain	0.125000	0.01
International Breast Cancer Center (IBCC), Spain	0.125000	0.01
Pangaea Oncology SA, Spain	0.125000	0.01
European University of Madrid (UEM), Spain	0.125000	0.01
MEDSIR - USA, United States of America (USA)	0.125000	0.01
Medica Scientia Innovation Research (MedSIR), Spain	0.125000	0.01
Hospital Universitario Torrejón, Spain	0.125000	0.01

Interested in Oncology and Carcinogenesis?